Tag: nasdaq:cmta

December 30, 2018

5 Top Weekly NASDAQ Biotech Stocks: Dova Up 41 Percent

Dova Pharmaceuticals, Sesen Bio, Adaptimmune Therapeutics, Mustang Bio and Equillium were last week's top gainers.
December 19, 2018

Biotech Outlook 2019: Will the Pressure Continue?

With 2018 coming to an end, what's the biotech outlook? Next year will bring new investing opportunities for those in...
October 2, 2018

Clementia Initiates Phase 1 Clinical Trial of Palovarotene Eye Drop Formulation in Healthy Volunteers

Clementia Pharmaceuticals (NASDAQ:CMTA), a clinical-stage biopharmaceutical company innovating treatments for people with ultra-rare bone disorders and other diseases, today announced the...
September 26, 2018

Clementia Announces Updated Phase 2 Part B Data on Palovarotene for FOP

Clementia Pharmaceuticals (Nasdaq:CMTA), a clinical-stage biopharmaceutical company innovating treatments for people with ultra-rare bone disorders and other diseases, today announced updated data...
August 16, 2018

Clementia Completes Phase 3 Move Trial Patient Enrolment

Clementia Pharmaceuticals announced on Thursday that it has completed enrolment for the Phase 3 Move trial with palovarotene.
August 16, 2018

Clementia Announces Completion of Enrollment in Phase 3 MOVE Trial for FOP

Clementia Pharmaceuticals (NASDAQ:CMTA), a clinical-stage company innovating treatments for individuals with ultra-rare bone disorders and other diseases, today announced the...